Androgen Receptor Cytosine, Adenine, Guanine Repeats, and Haplotypes in Relation to Ovarian Cancer Risk

Overview

Journal Cancer Res

Specialty Oncology

Date 2005 Jul 5

PMID 15994977

Citations 55

Authors

Kathryn L Terry

Immaculata De Vivo

Linda Titus-Ernstoff

Mei-Chiung Shih

Daniel W Cramer

Affiliations

Soon will be listed here.

Abstract

Biological and epidemiologic evidence suggest that androgen or its receptor may play a role in ovarian cancer pathogenesis. The most notable genetic factor influencing androgen receptor (AR) activity is the functional cytosine, adenine, guanine (CAG) repeat in which length is inversely proportional to its transactivational activity. Additional genetic variation due to single nucleotide polymorphisms in the AR gene may be captured through haplotypes. We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms (rs962458, rs6152, rs1204038, rs2361634, rs1337080, rs1337082) of the androgen receptor gene in 987 ovarian cancer cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003. We estimated haplotype frequencies and calculated odds ratios with 95% confidence intervals to evaluate the association between the haplotypes and the AR CAG microsatellite with ovarian cancer risk. We observed that carriage of two alleles with > or = 22 CAG repeats was associated with an increased risk of ovarian cancer compared with carriage of two alleles with <22 CAG repeats (covariate-adjusted odds ratios, 1.31; 95% confidence intervals, 1.01-1.69). Five common haplotypes in the AR gene were identified, but no association between these and ovarian cancer risk was observed. Our results suggest that possession of two long AR alleles (> or = 22 CAG repeats) may be associated with increased risk of ovarian cancer compared with women with two short AR alleles (<22 CAG repeats).

Citing Articles

A framework for assessing interactions for risk stratification models: the example of ovarian cancer.

Phung M, Lee A, McLean K, Anton-Culver H, Bandera E, Carney M J Natl Cancer Inst. 2023; 115(11):1420-1426.

PMID: 37436712 PMC: 10637032. DOI: 10.1093/jnci/djad137.

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.

Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H J Natl Cancer Inst. 2023; 115(5):539-551.

PMID: 36688720 PMC: 10165492. DOI: 10.1093/jnci/djad011.

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.

Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D Gynecol Oncol. 2022; 168:68-75.

PMID: 36401943 PMC: 10398872. DOI: 10.1016/j.ygyno.2022.10.018.

Effects of risk factors for ovarian cancer in women with and without endometriosis.

Phung M, Muthukumar A, Trabert B, Webb P, Jordan S, Terry K Fertil Steril. 2022; 118(5):960-969.

PMID: 36182623 PMC: 9969849. DOI: 10.1016/j.fertnstert.2022.07.019.

Lifetime ovulatory years and ovarian cancer gene expression profiles.

Sasamoto N, Stewart P, Wang T, Yoder S, Chellappan S, Hecht J J Ovarian Res. 2022; 15(1):59.

PMID: 35562768 PMC: 9102743. DOI: 10.1186/s13048-022-00995-1.

References

Suter N, Malone K, Daling J, Doody D, Ostrander E . Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev. 2003; 12(2):127-35. View

Yaron M, Levy T, Chetrit A, Levavi H, Sabah G, Schneider D . The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. Cancer. 2001; 92(5):1190-4. DOI: 10.1002/1097-0142(20010901)92:5<1190::aid-cncr1437>3.0.co;2-l. View

Stram D, Haiman C, Hirschhorn J, Altshuler D, Kolonel L, Henderson B . Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered. 2003; 55(1):27-36. DOI: 10.1159/000071807. View

Buchanan G, Yang M, Cheong A, Harris J, Irvine R, Lambert P . Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet. 2004; 13(16):1677-92. DOI: 10.1093/hmg/ddh181. View

Hu Y, Wang P, Yeh S, Wang R, Xie C, Xu Q . Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A. 2004; 101(31):11209-14. PMC: 509185. DOI: 10.1073/pnas.0404372101. View

Kuhnel R, de Graaff J, Rao B, STOLK J . Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987; 26(3):393-7. DOI: 10.1016/0022-4731(87)90106-3. View

La Spada A, Wilson E, Lubahn D, Harding A, Fischbeck K . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352(6330):77-9. DOI: 10.1038/352077a0. View

Edwards A, HAMMOND H, Jin L, Caskey C, Chakraborty R . Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992; 12(2):241-53. DOI: 10.1016/0888-7543(92)90371-x. View

Chadha S, Rao B, Slotman B, van Vroonhoven C, van der Kwast T . An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol. 1993; 24(1):90-5. DOI: 10.1016/0046-8177(93)90067-q. View

10.

Whittemore A, Harris R, Itnyre J . Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992; 136(10):1184-203. DOI: 10.1093/oxfordjournals.aje.a116427. View

11.

Thompson M, Adelson M . Aging and development of ovarian epithelial carcinoma: the relevance of changes in ovarian stromal androgen production. Adv Exp Med Biol. 1993; 330:155-65. DOI: 10.1007/978-1-4615-2926-2_12. View

12.

Elhaji Y, GOTTLIEB B, Lumbroso R, Beitel L, Foulkes W, Pinsky L . The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat. 2002; 70(2):109-16. DOI: 10.1023/a:1012942910375. View

13.

Haiman C, Brown M, Hankinson S, Spiegelman D, Colditz G, Willett W . The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 2002; 62(4):1045-9. View

14.

Edmondson R, Monaghan J, Davies B . The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer. 2002; 86(6):879-85. PMC: 2364138. DOI: 10.1038/sj.bjc.6600154. View

15.

Santarosa M, Bidoli E, Gallo A, Steffan A, Boiocchi M, Viel A . Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. Oncol Rep. 2002; 9(3):639-44. View

16.

Nelson K, Witte J . Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002; 155(10):883-90. DOI: 10.1093/aje/155.10.883. View

17.

Zaykin D, Westfall P, Young S, Karnoub M, Wagner M, Ehm M . Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered. 2002; 53(2):79-91. DOI: 10.1159/000057986. View

18.

Gabriel S, Schaffner S, Nguyen H, Moore J, Roy J, Blumenstiel B . The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-9. DOI: 10.1126/science.1069424. View

19.

Yeh S, Tsai M, Xu Q, Mu X, Lardy H, Huang K . Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A. 2002; 99(21):13498-503. PMC: 129702. DOI: 10.1073/pnas.212474399. View

20.

Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R . Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet. 2002; 10(11):724-8. DOI: 10.1038/sj.ejhg.5200880. View